Is Amphastar Pharmaceuticals, Inc. overvalued or undervalued?

As of 7 May 2025, the valuation grade for Amphastar Pharmaceuticals, Inc. has moved from very attractive to attractive. The company is currently assessed as undervalued. Key ratios include a P/E ratio of 10, an EV to EBITDA of 7.14, and a ROE of 19.18%.
In comparison to peers, Amphastar's P/E ratio of 10 is significantly lower than Corcept Therapeutics, Inc., which has a P/E of 60.68, indicating that Amphastar is trading at a more favorable valuation relative to its peers. Additionally, Prestige Consumer Healthcare, Inc. has a P/E of 20.10, further emphasizing Amphastar's attractive pricing. The company's recent stock performance has lagged behind the S&P 500, with a year-to-date return of -33.53% compared to the S&P 500's 2.44%, reinforcing the notion that it may be undervalued in the current market.